How PeptaHub Grades Peptide Evidence

PeptaHub uses four plain-language evidence labels on peptide profiles and guides.

**Strong** means the claim is supported by multiple well-designed human studies, usually randomized controlled trials, meta-analyses, major outcomes trials, or regulatory review documents. For example, weight-loss and glycemic-control claims for semaglutide and tirzepatide are strong because large phase 3 programs measured those endpoints directly in humans.

**Moderate** means the claim has human evidence but with limits: smaller trials, surrogate endpoints, shorter follow-up, mixed populations, or fewer independent replications. Moderate evidence can still be clinically meaningful, but it has more uncertainty than strong evidence.

**Preliminary** means the claim is grounded mainly in cell, animal, mechanistic, observational, early-phase, or indirect evidence. The mechanism may be plausible, but human efficacy and safety are not established. Many research-peptide claims sit here.

**Insufficient** means evidence is too thin, indirect, anecdotal, inconsistent, or absent to support the claim. A claim can be popular online and still be insufficient by evidence standards.

Different study types answer different questions. A cell-culture experiment can show that a peptide changes a receptor pathway, gene-expression pattern, or inflammatory marker under controlled lab conditions. That is useful mechanistic evidence, but it cannot tell you whether the compound improves outcomes in a human body.

Animal studies add whole-organism context: metabolism, circulation, tissue repair, immune response, and toxicity signals. They are stronger than cell studies, but translation is uncertain. Species differences, dosing route, disease model, and study design can all change whether a result applies to humans. A mouse tendon model is not the same as a human sports injury, and a rat metabolic model is not the same as long-term obesity treatment.

Human observational studies can detect associations in real-world populations, but they are vulnerable to confounding. Human randomized controlled trials are stronger because randomization reduces bias and predefined endpoints reduce selective interpretation. Large, replicated, blinded trials with clinically meaningful endpoints sit at the top of the practical hierarchy for efficacy claims.

A study is only as strong as the endpoint it actually measured. Surrogate markers are indirect measures that may or may not predict meaningful outcomes. Examples include a lab biomarker, receptor activation, body-composition proxy, or inflammatory marker. These can be useful early signals, but they do not prove a clinical benefit on their own.

Patient-important outcomes are stronger: weight change, HbA1c change in diabetes, cardiovascular events, kidney outcomes, wound closure, symptom scales validated for a condition, or adverse-event rates. Even then, context matters. A short trial can show short-term improvement without proving long-term durability or safety. A trial in one disease population may not apply to a different population.

PeptaHub separates the claim from the compound. One peptide can have strong evidence for one endpoint and insufficient evidence for another. Semaglutide has strong evidence for weight loss and glycemic control, but a separate claim about tendon repair would need its own evidence. Evidence does not transfer automatically from one outcome to another.

Peptide claims are often overstated when mechanistic plausibility is treated as proven human benefit. A receptor pathway may make a claim biologically plausible, but plausibility is not efficacy. A compound can bind a target, shift a biomarker, or improve an animal endpoint and still fail in human trials.

Another pattern is dose extrapolation. Animal studies often use doses, routes, and timing that do not map cleanly to human protocols. Converting dose by body weight alone can be misleading; pharmacokinetics, receptor occupancy, half-life, formulation, and route all matter.

A third pattern is selective citation. Positive studies are easier to market than null or negative results. Small early studies can look impressive because of chance, flexible endpoints, or publication bias. Responsible interpretation asks what the full evidence set shows, whether independent groups reproduced the result, and whether the study measured the claim being made.

Finally, anecdotes can identify questions worth studying but cannot establish effect. Online reports lack controls, blinding, standardized products, confirmed diagnoses, and systematic adverse-event capture. PeptaHub treats anecdotes as context, not proof.

Evidence labels are a map of uncertainty, not a permission slip. A strong label means a specific claim has strong published support in the studied population and context; it does not mean a compound is appropriate for every person or every use. A preliminary label means the idea is not baseless, but the human evidence is not settled. An insufficient label means the claim should not be treated as established.

When reading a peptide profile, match the label to the exact claim. Ask: Was this tested in humans? Was it randomized? How many participants were studied? Was the endpoint clinically meaningful? Was the compound the same as the one being discussed? Was the route and formulation comparable? Are safety data available for the same population and duration?

PeptaHub updates labels as the evidence changes. New trial readouts, regulatory reviews, safety warnings, or failed replication can move a claim up or down. The goal is not to make every peptide look good; the goal is to make the strength of each claim visible.